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Results FOLFOX reduced the pain threshold in response 
to mechanical noxious and thermal (cold) non-noxious 
stimuli beginning from day 14 up to day 42 comparably to 
oxaliplatin alone. A fifth FOLFOX injection enhanced the 
severity but not the duration of painful alterations. Spon-
taneous activity, behavioural, autonomic, and neurological 
functions were also affected, whereas the motor coordina-
tion was not altered. On day 22, duloxetine (15 mg kg−1, per 
os), morphine (10 mg kg−1, subcutaneously), or pregaba-
lin (20 mg kg−1, per os), acutely administered, reduced the 
FOLFOX-dependent hypersensitivity. Repeated treatments 
with dimiracetam (150 mg kg−1, per os, twice daily, from 
day 22) significantly protected rats from FOLFOX-induced 
alterations of pain threshold as well as from autonomic and 
neurological impairments taking effect after 7 days treat-
ment. Pregabalin repeatedly administered (20 mg kg−1, per 
os, twice daily, from day 22) was less effective in reducing 
mechanical hypersensitivity.
Conclusion A clinically consistent model of FOL-
FOX-induced neurotoxicity has been developed in rats. 
Dimiracetam fully reduced hypersensitivity and neurologi-
cal alterations showing a relevant profile as anti-neuropathic 
resource.
Keywords FOLFOX · Oxaliplatin · Pain model · 
Neuropathy · Dimiracetam · Pregabalin · HT-29
Introduction
The addition of oxaliplatin to 5-fluorouracil (5-FU) and 
leucovorin (LV) proved to be a significant improvement in 
the treatment of metastatic colon cancer [1]. This combi-
nation, called the FOLFOX regimen, has become part of 
the world-wide standard of care for the adjuvant and the 
Abstract 
Background and aim The FOLFOX family of chemother-
apy regimens are hampered by the development of a painful 
neuropathy. Current clinical treatments are inadequate, and 
furthermore, the research of innovative drugs is strongly 
disadvantaged by the absence of a preclinical model based 
on the complete mixture of FOLFOX components. The aim 
of this study was to set up a rat model of FOLFOX-induced 
neuropathy in rats, validate its predictability by reference 
drugs, and evaluate the effectiveness of the new anti-neuro-
pathic compound dimiracetam.
Methods Male Sprague–Dawley rats were treated intra-
peritoneally with the FOLFOX components (6 mg kg−1 
oxaliplatin, 50 mg kg−1 5-FU, 90 mg kg−1 leucovorin cal-
cium salt) or oxaliplatin alone (6 mg kg−1) on days 0, 7, 
14, and 21, whereas a separate group received one more 
injection of FOLFOX on day 28. Pain behavioural measure-
ments (paw pressure, cold plate, and electronic Von Frey 
tests) and motor coordination (Rota-rod test) were assessed 
before and after treatments. Behavioural, motor, neurologi-
cal, and autonomic parameters (open field and Irwin tests) 
were evaluated.
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palliative treatment of the disease [2]. Among others, the 
prominent side effect of FOLFOX therapy is a debilitating, 
dose-limiting neurotoxicity, which leads to a painful sensory 
neuropathy. Symptoms evolve in two distinct phases. The 
acute phase, experienced by 85–95% of treated patients, is 
characterized by an increased sensitivity to touching cold 
items or swallowing cold liquids, throat discomfort, and 
muscle cramping. It is most pronounced 3 days after a given 
oxaliplatin infusion [3]. A chronic phase comprises sensory 
impairment of the distal peripheral nerves of the extremities. 
Chronic symptoms affect roughly 60, 40, 20, and 10% of 
treated subjects at 1, 6 months, 1, and 2 years after comple-
tion of the FOLFOX regimen, respectively [4–6].
The symptoms of neurotoxicity observed during and after 
FOLFOX therapy are largely attributable to oxaliplatin [5]. 
Monotherapy with 5-FU rarely induced neurotoxicity, but 
fluoropyrimidine metabolites could trigger further nervous 
alterations [7]. On the other hand, clinical reports are mainly 
based on the evaluation of the FOLFOX combination effects 
without distinction among single components and knowl-
edge about possible additive effects. The molecular bases of 
the neurotoxicity evoked by FOLFOX therapy in its entirety 
are unknown, even because the lack of a preclinical model 
of FOLFOX neuropathy. The currently available data about 
the most neurotoxic component oxaliplatin reveal a complex 
panel of damages (peripheral nerves, dorsal root ganglia, and 
central nervous system areas) and altered responses due to 
maladaptive plasticity (of both neurons and glia; [8–11]) 
that may be complicated by the presence of 5-FU and LV.
The symptoms arisen after FOLFOX therapy signifi-
cantly affect patients’ daily activities and quality of life, and 
they are difficult to treat: randomized, controlled clinical 
trials have to-date demonstrated only for duloxetine a mod-
est treatment effect [12, 13]. Thus, the discovery of novel 
effective strategies remains a crucial objective. Recently, 
dimiracetam, a racetam derivative with nootropic properties, 
has been proposed as a pain reliever active against chemo-
therapy-induced neuropathy (CIN) distinguished by an opti-
mal safety profile. It has been shown to be a potent inhibi-
tor of glutamate-induced glutamate release in the rat spinal 
cord: dimiracetam inhibits NMDA + glycine-stimulated 
[3H]-D-aspartate release from rat spinal synaptosomes with 
an IC50 between 10 and 20 nM [14]. Glutamate-induced 
glutamate release is believed to be directly involved in sen-
sitization of spinal and central pain pathways [15].
The present research undertook the development of an 
animal model of chemotherapy-induced neuropathic pain 
evoked by the combined administration of all FOLFOX 
components. The hypersensitivity to mechanical and ther-
mal noxious and non-noxious stimuli, as well as behavioural, 
neurological, autonomic parameters, and motor functions 
were analyzed to offer a clinical relevant tool to study the 
pathophysiological mechanisms of FOLFOX neurotoxicity 
and screen new treatments. The properties of dimiracetam 
were characterized in comparison with currently applied 
drugs.
Materials and methods
Animals
Male Sprague–Dawley (SD) rats (Envigo, Varese, Italy) 
weighing approximately 200–250 g at the beginning of the 
experimental procedure were used. Animals were housed 
in CeSAL (Centro Stabulazione Animali da Laboratorio, 
University of Florence) and used at least 1 week after their 
arrival. Four rats were housed per cage (size 26 × 41 cm) 
kept at 23 ± 1 °C with a 12 h light/dark cycle, with lights 
on at 7 a.m; they were fed a standard laboratory diet and 
tap water ad libitum. All animal manipulations were carried 
out according to the Directive 2010/63/EU of the European 
parliament and of the European Union council (22 Septem-
ber 2010) on the protection of animals used for scientific 
purposes. The ethical policy of the University of Florence 
complies with the Guide for the Care and Use of Labora-
tory Animals of the US National Institutes of Health (NIH 
Publication no. 85-23, revised 1996; University of Florence 
assurance number: A5278-01). Formal approval to conduct 
the experiments described was obtained from the Animal 
Subjects Review Board of the University of Florence. Exper-
iments involving animals have been reported according to 
ARRIVE guidelines [16]. All efforts were made to minimize 
animal suffering and to reduce the number of animals used.
Treatments
Oxaliplatin (6 mg kg−1) or a mixture of FOLFOX compo-
nents (6 mg kg−1 oxaliplatin, 50 mg kg−1 5-FU, 90 mg kg−1 
LV calcium salt) were administered intraperitoneally (i.p.) 
on days 0, 7, 14, and 21. Oxaliplatin was dissolved in 5% 
glucose; the other compounds were dissolved in saline. 
Regarding to the FOLFOX regimen, 5-FU and LV were 
administered 2 h after the oxaliplatin administration. Doses 
were established accordingly with Robinson et al. [17]. On 
day 28, FOLFOX-treated animals were divided into two 
groups, one of them, namely, FOLFOX (5), was treated once 
again on the same day. The other group received four total 
administrations—FOLFOX (4).
The effect of the pain relieving drugs was evaluated 
after acute or repeated treatment. As regards the acute 
treatment, duloxetine (15 mg kg−1, per os—p.o.), mor-
phine (10  mg  kg−1, subcutaneously—s.c.), pregabalin 
(20 mg kg−1, p.o.), and dimiracetam (150 mg kg−1, p.o.) 
were administered on day 22 or on day 28. For the chronic 
treatment, dimiracetam (150 mg kg−1, p.o.), pregabalin 
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(20 mg kg−1, p.o.), and duloxetine (15 mg kg−1, p.o.) were 
administered daily bis in die (b.i.d.) for three consecutive 
weeks (starting from day 22). Morphine was dissolved in 
saline, while dimiracetam, pregabalin, and duloxetine were 
suspended in 1% carboxymethylcellulose sodium salt. 
Body weight was constantly measured during the experi-
ment, and results obtained during treatments are reported 
in the Supplementary Figure S1.
Paw pressure test
Paw mechanical sensitivity was determined using a Ran-
dall and Selitto apparatus exerting a force that increased at 
constant rate (32 g s−1). The threshold stimulus at which 
rats withdrew the paw was evaluated before and at differ-
ent timepoints after treatment. Results represent the group 
mean of mechanical thresholds expressed as grams. To 
avoid any possible damage to the rats’ paw, the maximum 
applied force was fixed at 150 g [18].
Cold plate test
T h e  r a t s  we re  p l a c e d  i n  a  s t a i n l e s s  b ox 
(12 cm × 20 cm × 10 cm) with a temperature-controlled 
cold steel plate as floor. The temperature of the cold plate 
was kept constant at 4 °C ± 1 °C. Pain-related behaviours 
(i.e., lifting and licking of the hind paw) were observed 
and the time (s) of the first sign was recorded. The cut-
off time of the latency of paw lifting or licking was set at 
60 s [10].
Von Frey test
The rats were placed in 20 × 20 cm plexiglas boxes equipped 
with a metallic screen-mesh floor, 20 cm above the bench. 
A habituation of 15 min was allowed before the test. An 
electronic Von Frey hair unit (Ugo Basile, Varese, Italy) was 
used: the withdrawal threshold was evaluated by applying 
a force ranging from 0 to 50 g with a 0.2 g accuracy. The 
punctuate stimulus was delivered to the mid-plantar area of 
each posterior paw from below the meshy floor through a 
plastic tip and the withdrawal threshold was automatically 
displayed on the screen. The paw sensitivity threshold was 
defined as the minimum pressure required to elicit a robust 
and immediate withdrawal reflex of the paw. Voluntary 
movements associated with locomotion were not taken as a 
withdrawal response. Stimuli were applied on each posterior 
paw with an interval of 5 s. The measure was repeated five 
times and the final value was obtained by averaging the five 
measures [10].
Open field test
Locomotive activity was assessed by the open-field test. The 
observation apparatus consisted of a 60 × 60 cm wooden box 
with the field bordered by 45 cm high sidewalls. Time spent 
in the corners and in the center; number of rearing; number 
of crossings to the center and the periphery; and spontaneous 
activity and inactivity of each rat were monitored for 20 min. 
The data were analyzed using the X-Plo-rat software system 
version 3.3.
Irwin test
Each rat was individually placed in a transparent cage 
(26 × 41  cm), and 26 neurobehavioural or physiologi-
cal parameters were systematically assessed according to 
Irwin (1968) [19] 4 and 7 weeks after the beginning of the 
experiment.
Behavioural, autonomic, and neurological manifesta-
tions produced by compound administration in rats were 
evaluated: motor displacement, motor reflexes, stereotyp-
ies, grooming, reaction to painful or environmental stimuli 
(analgesia, irritability), startle response, secretions, excre-
tions, respiratory movements, skin colour and temperature, 
piloerection, exophthalmos, eyelid and corneal reflexes, 
muscle tone, ataxia, tremors, head twitches, jumps, convul-
sions, Straub tail, and other signs or symptoms. For postural 
reflexes (righting reflex) and other signs such as piloerec-
tion, exophthalmia (exaggerated protrusion of the eyeball), 
ataxia, tremors, and Straub tail, only presence or absence 
was recorded. Skin colour was evaluated qualitatively (pale, 
red, or purple); other signs were evaluated semi-quantita-
tively, according to the observer’s personal scale (0 to + 4, 
− 4 to 0, or − 4 to + 4). The terms sedation and excitation 
express the final interpretation of a group of signs: reduced 
motor activity, reduced startle response, eyelid ptosis, and 
reduced response to manual manipulation, for the former; 
and increased motor activity, increased startle response, 
increased response to manual manipulation, and exophthal-
mia, for the latter. Hyperactivity includes running, jumps, 
and attempts to escape from the container. Trained observers 
not informed about the specific treatment of each animal 
group carried out this test.
Rota-rod test
Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a 
base platform and a rotating rod with a diameter of 6 cm and a 
non-slippery surface. The rod was placed at a height of 25 cm 
from the base. The rod, 36 cm in length, was divided into four 
equal sections by five disks. Thus, up to four rats were tested 
simultaneously on the apparatus, with a rod-rotating speed 
of 10 rpm. The integrity of motor coordination was assessed 
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based on the number of falls from the rod for a maximum of 
600 s. After a maximum of six falls from the rod, the test was 
suspended and the time was recorded. Each rat was assessed 
once, and the group mean average score was calculated.
Cell culture and treatments
The human colon cancer cell line HT-29 was obtained from 
American Type Culture Collection (Rockville, MD, USA). 
HT-29 were cultured in DMEM high glucose with 20% FBS 
in 5%  CO2 atmosphere at 37 °C. Media contained 2 mM l-glu-
tamine, 1% essential aminoacid mix, 100 IU ml−1 penicillin, 
and 100 μg ml−1 streptomycin (Sigma, Milan, Italy). HT-29 
cells were plated in 96-wells cell culture (1 × 104/well) plates, 
and after 48 h, they were treated with increasing concentra-
tions of FOLFOX components for 24 or 48 h. The molar ratio 
among oxaliplatin/5-FU/LV used in vivo was maintained 
(6/50/90 mg kg−1 are 15/384/176 μg kg−1). Experiments were 
repeated in the absence and in the presence of dimiracetam 
(100 µM).
Cell viability assay
HT-29 cell viability was evaluated by the reduction of 
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) as an index of mitochondrial compartment functional-
ity. Cells were plated into 96-well cell culture plates, and after 
48 h, they were treated as previously described. After exten-
sive washing, 1 mg ml−1 MTT was added into each well and 
incubated for 30 min at 37 °C. After washing, the formazan 
crystals were dissolved in 150 μl dimethyl sulfoxide. The 
absorbance was measured at 550 nm [8].
Statistical analysis
Behavioural measurements were performed on ten rats for 
each treatment carried out in two different experimental 
sets. Cell culture measurements were performed in sextu-
plicate on at least three different cell batches. All experi-
mental results (excepted for the Irwin test) were expressed 
as means ± SEM and the analysis of variance was performed 
by two-way ANOVA. A Bonferroni’s significant difference 
procedure was used as post-hoc comparison. P values ≤ 0.05 
were considered statistically significant.
Results
Pain threshold measurements: effect of FOLFOX 
treatment
On days 0, 7, 14, and 21, FOLFOX (4) (6 mg kg−1 oxalipl-
atin, 50 mg kg−1 5-FU, and 90 mg kg−1 leucovorin calcium 
salt) or oxaliplatin alone (6 mg kg−1) was administered i.p. 
once a week for four times; furthermore, a separate group 
received one more injection of FOLFOX (5) on day 28. Pain 
measurements were assessed before treatment and 24 h after, 
up to day 28, and once a week up to day 63. As shown in the 
Supplementary Figure S1, all treatments reduced the body 
weight increase in comparison with vehicle-treated animals.
As measured by the paw pressure test, FOLFOX (4) low-
ered the paw withdrawal threshold in response to a nox-
ious mechanical stimulus starting from day 14 and pick-
ing on day 29 [43.3 ± 0.7 g, FOLFOX (4) vs. 66.6 ± 2.3 g, 
vehicle]. Oxaliplatin treatment also reduced the paw with-
drawal threshold starting from day 14 and picking on day 29 
(46.7 ± 1.7 g, oxaliplatin vs. 66.6 ± 2.3 g, vehicle). The effect 
of FOLFOX was numerically greater than oxaliplatin alone, 
but did not reach the threshold of statistical significance. 
The paw withdrawal threshold induced by a fifth injection 
of FOLFOX picked in severity on day 42 [41.5 ± 1.6 g, FOL-
FOX (5) vs. 69.4 ± 1.5 g, control]; this peak was lower than 
that achieved in the FOLFOX (4) group. By day 64, the 
paw-withdrawal threshold of the FOLFOX groups had not 
quite returned to the level of the injection vehicle-treated 
group, whereas the oxaliplatin group had more completely 
recovered (Fig. 1a).
The cold plate test measured the response to a thermal 
non-noxious stimulus as the time latency of licking or 
retracting paw after a cold stimulus. As shown in Fig. 1b, 
both FOLFOX and oxaliplatin alone significantly enhanced 
the sensitivity to cold from day 14 until, day 35 and day 42, 
respectively, and picking on day 28 [15.0 ± 0.7 s, FOLFOX 
(4)] and day 35 (12.5 ± 0.5 s, oxaliplatin), respectively. A 
fifth injection of FOLFOX reduced the pain threshold in 
response to a thermal non-noxious stimulus up to day 42, 
reaching a nadir on that day [10.9 ± 0.5 s, FOLFOX (5) vs. 
23.6 ± 0.8 s, control] (Fig. 1b).
Neither FOLFOX nor oxaliplatin alone altered at any 
timepoint the pain sensitivity in response to a mechanical 
non-noxious stimulus in the Von Frey apparatus (Fig. 1c).
Pain threshold measurements: effect of single doses 
of duloxetine, morphine, pregabalin, and dimiracetam 
against FOLFOX-induced hypersensitivity
Following single doses of duloxetine (15 mg kg−1, p.o.), 
morphine (10 mg kg−1, s.c.), pregabalin (20 mg kg−1, p.o.), 
or dimiracetam (150 mg kg−1, p.o.) on FOLFOX (4)-treated 
or oxaliplatin-treated rats on day 22, or on FOLFOX 
(5)-treated animals on day 28, the response to a mechani-
cal noxious stimulus was measured over time up to 45 min 
after administration. As depicted in Fig. 2a, duloxetine sig-
nificantly decreased the hypersensitivity induced by FOL-
FOX (4) up to 30 min exerting the maximum effect 15 min 
after treatment [57.9 ± 0.5 g, FOLFOX (4) + duloxetine] and 
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morphine and pregabalin reduced FOLFOX (4)-induced 
hypersensitivity 15 min after injection [56.3 ± 0.3 g, FOL-
FOX (4) + morphine; 52.3 ± 0.3 g, FOLFOX (4) + pregaba-
lin]. Otherwise, dimiracetam had no effect (Fig. 2a). Similar 
single-dose profiles were also evident in FOLFOX (5)- and 
in oxaliplatin-treated rats (Fig. 2b, c).
Pain threshold measurements: effect of repeated doses 
of duloxetine, morphine, pregabalin, and dimiracetam 
against FOLFOX-induced hypersensitivity
To evaluate the efficacy of compounds after repeated 
administrations, FOLFOX (4)-treated animals were daily 
p.o. treated b.i.d. with pregabalin (20 mg kg−1), dulox-
etine (15 mg kg−1), or dimiracetam (150 mg kg−1) starting 
from day 22 for four consecutive weeks. The response to 
a mechanical noxious stimulus was measured every week 
over time until 24 h after administration. As shown in Fig. 3, 
dimiracetam significantly increased the pain threshold of 
FOLFOX-injected rats, starting from day 28. Pregabalin was 
effective from day 35. The efficacy of both compounds was 
not different among 1 and 24 h after treatment suggesting 
a stable improved pain threshold. Repeated administrations 
of duloxetine did not modify the hypersensitivity induced 
by FOLFOX.
Behavioural, neurological, and motor functions: 
effect of duloxetine, pregabalin, and dimiracetam 
on FOLFOX-treated animals
As evaluated by the open-field test (Table 1), FOLFOX 
treatment, on day 22, significantly reduced the number of 
rearings in comparison with the vehicle group (19.4 ± 2.9, 
FOLFOX vs. 55.2 ± 6.3, vehicle). The spontaneous activity 
was also reduced (141.2 ± 20.4, FOLFOX vs. 387.1 ± 32.8, 
vehicle).
On days 22 and 42, behavioural, autonomic, and neuro-
logical parameters were evaluated giving an arbitrary score 
(from 0 to ± 4), by the Irwin test. On day 22, FOLFOX 
reduced spontaneous activity, reactivity, and curiosity, 
whereas the frequencies of tremors, ataxia, piloerections, 
anemia, and hypothermia were increased (Table 2). Other 
observational categories were not significantly affected. On 
day 42, following 21 days of twice-daily oral treatment with 
Fig. 1  Pain-related measurements. Oxaliplatin (6.0  mg  kg−1 
i.p.) (blue circle) or FOLFOX (oxaliplatin 6.0  mg  kg−1 i.p/5-FU 
50 mg kg−1 i.p./leucovorin 90 mg kg−1 i.p.) [FOLFOX (4) red circle] 
were injected on days 0, 7, 14, and 21 after the behavioural meas-
urements. On day 28, animals were divided into two groups, one 
was treated once again on the same day with FOLFOX [FOLFOX(5) 
green circle]. On days 0, 1, 7, 8, 14, 15, 21, 22, 28, 29, 35, 42, 49, 
and 63, the sensibility to a noxious mechanical stimulus was meas-
ured by paw pressure test (a), the response to a thermal non-noxious 
stimulus was evaluated by cold plate test measuring the latency (s) 
to pain-related behaviours (lifting or licking of the paw) (b), and 
the withdrawal threshold in response to a non-noxious mechanical 
stimulus was evaluated by the Von Frey apparatus (c). Control rats 
were treated with vehicle. Each value represents the mean ± SEM 
of ten rats per group, performed in two different experimental sets. 
*P < 0.05 and **P < 0.01 vs. vehicle + vehicle-treated animals
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dimiracetam, these FOLFOX effects were nearly completely 
reversed; pregabalin was similarly effective, whereas dulox-
etine was less effective (Table 3).
Motor coordination was assessed by the Rota-rod appa-
ratus, before and 24 h after FOLFOX administration; dur-
ing the repeated treatments with dimiracetam, pregabalin 
and duloxetine measurements were performed once a week. 
Neither FOLFOX nor compounds altered the number of falls 
in 600 s in comparison with the control group (Table 4).
Dimiracetam effects on FOLFOX-dependent lethality 
on colon cancer cells
To evaluate the potential interaction between dimiracetam 
treatment and the therapeutic property of FOLFOX, the via-
bility of the human colon cancer cell line HT-29 was meas-
ured. Table 5 shows the lack of influence of dimiracetam on 
the concentration-dependent FOLFOX lethal effect after 24 
and 48 h incubation.
Fig. 2  Mechanical noxious 
stimulus. Effect of duloxetine, 
morphine, pregabalin, and 
dimiracetam. Acute treatment. 
Duloxetine (15 mg kg−1, p.o.), 
morphine (10 mg kg−1, s.c.), 
pregabalin (20 mg kg−1, p.o.), 
or dimiracetam (150 mg kg−1, 
p.o.) was administered on day 
22 on FOLFOX (4)- (a) and 
oxaliplatin-treated (b) animals 
or on day 28 on FOLFOX 
(5)-treated (c) animals and 
the response to a mechanical 
noxious stimulus was measured 
0, 15, 30, and 45 min after 
injection by the paw pressure 
test. Control rats were treated 
with vehicles. Each value 
represents the mean ± SEM of 
ten rats per group, performed in 
two different experimental sets. 
**P < 0.01 vs. vehicle + vehi-
cle treated rats; ^P < 0.05 and 
^^P < 0.01 vs. time 0 of the same 
group
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Discussion
A rat model of FOLFOX-induced neuropathy was devel-
oped. Animals weekly treated with the complete antineo-
plastic regimen, oxaliplatin, 5-FU and LV, received in 4 
weeks a cumulative oxaliplatin dose of 24 mg kg−1, corre-
sponding to the clinically relevant dose [20] of 888 mg m−2 
for the human body, as calculated by the body surface area 
(BSA) normalization method [21]. The FOLFOX-regimen 
induced in rats hypersensitivity to mechanical noxious and 
thermal (cold) non-noxious stimuli, which untreated per-
sists for at least 5 weeks after the last FOLFOX adminis-
tration. In the present model, we could not detect a change 
from baseline in the paw-withdrawal threshold in response 
to a mechanical non-noxious stimulus. Another injection 
of FOLFOX (the fifth, reaching 30 mg kg−1 of cumulative 
oxaliplatin, corresponding to 1110 mg m−2) enhanced the 
severity of the hypersensitivity to both mechanical noxious 
and thermal (cold) non-noxious stimuli, but the course of 
recovery in the drug-free follow-up period was similar to 
the FOLFOX (4).
Behavioural and motor parameters were impaired, since 
FOLFOX strongly reduced the curiosity and the spontane-
ous activity of animals even if motor coordination was not 
altered. A deeper investigation on behavioural, neurologi-
cal, and autonomic functions highlighted reduced reactiv-
ity and curiosity concomitantly with increased frequency 
of tremors, ataxia, anemia, and hypothermia. These altera-
tions were mighty evident after the last administration of 
FOLFOX and, although reduced, still present 3 weeks after 
treatment discontinuation.
Neuropathy is not a common complication of 5-FU 
therapy [20]. However, some patients have experienced 
5-FU-induced neurotoxicity, caused by the accumula-
tion of the fluoropyrimidine metabolites. The alteration 
of the neurophysiological profile induced by 5-FU may 
make nerve fibers prone to further degeneration [7]. 
Otherwise, as evidenced by Andrè and colleagues in the 
Fig. 3  Mechanical noxious stimulus. Effect of dimiracetam, prega-
balin, and duloxetine. Chronic treatment. Starting from day 22, FOL-
FOX-injected rats (four administrations) were orally administered 
b.i.d. with dimiracetam (150  mg  kg−1), pregabalin (20  mg  kg−1), 
or duloxetine (15  mg  kg−1) daily for three consecutive weeks. The 
response to a mechanical noxious stimulus was assessed by the paw 
pressure test 0, 1, 3, 6, and 24 h after injection on days 22, 28, 35, 
and 42. Each value represents the mean ± SEM of ten rats per group, 
performed in two different experimental sets. **P < 0.01 vs. vehi-
cle + vehicle-treated animals; ^P < 0.05 and ^^P < 0.01 vs. FOL-
FOX + vehicle-treated animals
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MOSAIC trial, the addition of the platinum-derivative to 
the combination of 5-FU/LV increased the rate of patients 
manifesting chronic neuropathy [22]. The present FOL-
FOX model shows few, if any, differences over the sim-
pler oxaliplatin-only model, except that recovery of in the 
drug-free follow-up period was more complete, confirm-
ing the main neurotoxic role of the platinum derivative. 
In humans, the association with 5-FU and LV allows a 
decrease of oxaliplatin cumulative dosage [23], however, 
introducing new variables in the mechanisms of neuropa-
thy as well as more possibilities of interactions with pain 
relieving drugs. To note, the pathophysiology of FOLFOX 
neurotoxicity has not been investigated yet and molecular 
mechanisms occurring in the chronic form of oxaliplatin-
induced neuropathy remain unclear. Morphological exami-
nation revealed that the primary target of oxaliplatin, and 
more in general of platinum compounds, is the dorsal root 
ganglia (DRGs), where the accumulation of the antineo-
plastic agent triggers nuclear damage [10, 24]. Molecular 
modifications occurred both in DRGs and in peripheral 
nerves [10, 25, 26]. To note, despite the low oxaliplatin 
capability to cross the blood brain barrier [27, 28], dra-
matic alterations of the CNS were shown. Oxidative dam-
ages [29], increased hyper-excitability of the nociceptive-
specific neurons in the dorsal horn of the spinal cord [8, 
9], were related to oxaliplatin-induced pain. A maladaptive 
plasticity involves also the glial cells, strongly involved 
in the development and maintenance of neuropathic pain 
states [30, 31]. The activation of astrocytes continuously 
accompanies the treatment with the antineoplastic agent, 
Table 1  Open-field test: effect of FOLFOX on behavioural and loco-
motor activity
On day 22, after four administrations of FOLFOX, behavioural and 
locomotor activity functions were assessed using the open-field test. 
Time spent in the corners and in the center; number of rearings; num-
ber of crossings to the center or to the periphery; spontaneous activ-
ity; and spontaneous inactivity of each rat were monitored for 20 min 
and analyzed using the X-plo-rat software system. Each value repre-
sents the mean ± S.E.M. of ten rats per group performed in two differ-
ent experimental sets
**P < 0.01 vs. vehicle + vehicle-treated animals
Treatments
Vehicle + vehicle FOLFOX + vehicle
Time spent in the corners (s) 977.8 ± 22.0 1053.4 ± 36.3
Time spent in the center (s) 21.5 ± 4.4 11.8 ± 4.3
No. of rearings 55.2 ± 6.3 19.4 ± 2.9**
No. of crossings to the center 6.6 ± 1.5 2.4 ± 1.2
No. of crossings to the 
periphery
155.3 ± 21.4 90.2 ± 20.8
Spontaneous inactivity (s) 812.9 ± 32.8 1099.6 ± 40.3**
Spontaneous activity (s) 387.1 ± 32.8 141.2 ± 20.4**
Table 2  Irwin test, day 22: effect of FOLFOX on behavioural, auto-
nomic, and neurological parameters
On day 22, after four administrations of FOLFOX, the Irwin test was 
performed in the rat; it involves subjective assessment of behavioural, 
autonomic, and neurological manifestations in spontaneous, freely 
moving animals. Skin colour was evaluated qualitatively; other signs 
were evaluated semi-quantitatively, according to the trained observ-
er’s personal scale (0 to + 4, − 4 to 0, or − 4 to + 4). Each value rep-
resents the mean ± SEM of ten rats per group, performed in two dif-
ferent experimental sets
*P < 0.05 vs. vehicle + vehicle treated rats
Treatments Limits
Vehicle + vehicle FOLFOX + vehicle
Behaviour
 Spontaneous 
activity
4 ± 0 1.2 ± 0.2* 4–0
 Passivity 0 ± 0 3.1 ± 0.3* 0–4
 Cleaning 4 ± 0 3.1 ± 0.3 4–0
 Curiosity 4 ± 0 2.2 ± 0.3* 4–0
 Reactivity 4 ± 0 0.9 ± 0.1* 4–0
 Vocalization 0 ± 0 0 ± 0 0–4
C.N.S. excitement
 Straub tail 0 ± 0 0 ± 0 0–4
 Tremors 0 ± 0 3.3 ± 0.4* 0–4
 Convulsions 0 ± 0 0 ± 0 4–0
Movement
 Ataxia 0 ± 0 2.3 ± 0.1* 0–4
 Stereotipies 0 ± 0 1.1 ± 0.4 0–4
 Straightening 
reflex
4 ± 0 4 ± 0 4–0
Muscular tone
 Physical strength 4 ± 0 2.4 ± 0.8 4–0
Reflexes
 Palpebral reflex 4 ± 0 3 ± 0.4 4–0
Autonomic signs
 Piloerection 0 ± 0 3.2 ± 0.2* 0–4
 Exolphthalmos 0 ± 0 1.8 ± 0.5 0–4
 Cyanosis 0 ± 0 0 ± 0 0–4
 Flush 0 ± 0 0 ± 0 0–4
 Pallor 0 ± 0 3.8 ± 0.2* 0–4
 Palpebral opening 4 ± 0 4 ± 0 4–0
 Salivation 0 ± 0 0 ± 0 0–4
 Lacrimation 0 ± 0 0 ± 0 0–4
 Hypo-hyperther-
mia
0 ± 0 − 2.1 ± 0.1* − 4/+ 4
 Writhing 0 ± 0 0 ± 0 0–4
Toxicity
 Immediate death 0 ± 0 0 ± 0 0–4
 Delayed death 
(48 h)
0 ± 0 0 ± 0 0–4
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suggesting a complex involvement of astrocytes in pain 
chronicization [10, 11, 32].
Although the evidences collected up to now about the 
neurotoxicity evoked by the platinum derivative, effective 
treatments against FOLFOX-induced neuropathy are lack-
ing. Duloxetine is the only recommended intervention. Nev-
ertheless, it is not completely effective and did not work 
for everyone [33]. Tricyclic antidepressants are not recom-
mended but clinicians may use them after discussion with 
patients about the limited effectiveness. The antiepileptic 
drugs, pregabalin and gabapentin, have not well-established 
efficacy as resulted from clinical trials, but given the lim-
ited options for managing neuropathy, their clinical use is 
encouraged [13].
Table 3  Irwin test, day 42: effect of dimiracetam, pregabalin, duloxetine on FOLFOX-induced behavioural, autonomic and neurological altera-
tions
On day 42, following 21 days of twice daily oral administration of dimiracetam (150  mg  kg−1), pregabalin (20  mg  kg−1), or duloxetine 
(15  mg  kg−1), the Irwin test was performed on FOLFOX-injected rats (four administrations). Skin colour was evaluated qualitatively; other 
signs were evaluated semi-quantitatively, according to the observer’s personal scale (0 to + 4, − 4 to 0, or − 4 to + 4). Each value represents the 
mean ± S.E.M. of ten rats per group, performed in two different experimental sets
*P < 0.05 vs. vehicle + vehicle; ^P < 0.05 vs. FOLFOX + vehicle
Treatments Limits
Vehicle + vehicle FOLFOX + vehicle FOL-
FOX + dimiracetam
FOL-
FOX + prega-
balin
FOL-
FOX + duloxetine
Behaviour
 Spontaneous activity 4 ± 0 2 ± 0.1* 4 ± 0^ 4 ± 0^ 2.8 ± 0.3 4–0
 Passivity 0 ± 0 2.1 ± 0.2* 0 ± 0^ 0 ± 0^ 1.4 ± 0.5 0–4
 Cleaning 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4–0
 Curiosity 4 ± 0 2.7 ± 0.1* 4 ± 0^ 4 ± 0^ 4 ± 0^ 4–0
 Reactivity 4 ± 0 2.8 ± 0.1* 4 ± 0^ 4 ± 0^ 3.1 ± 0.2 4–0
 Vocalization 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
C.N.S. excitement
 Straub tail 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Tremors 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Convulsions 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 4–0
Movement
 Ataxia 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Stereotipies 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Straightening reflex 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4–0
Muscular tone
 Physical strength 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4–0
Reflexes
 Palpebral reflex 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4–0
Autonomic signs
 Piloerection 0 ± 0 2.1 ± 0.2* 1.1 ± 0.1^ 1 ± 0.2^ 1.3 ± 0.1^ 0–4
 Exolphthalmos 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Cyanosis 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Flush 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Pallor 0 ± 0 3 ± 0.2* 1.2 ± 0.1^ 1.2 ± 0.1^ 3 ± 0.3 0–4
 Palpebral opening 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4 ± 0 4–0
 Salivation 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Lacrimation 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Hypo-hyperthermia 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 − 4/+ 4
 Writhing 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
Toxicity
 Immediate death 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
 Delayed death (48 h) 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0–4
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Table 4  Rota-rod test: 
evaluation of motor 
coordination
From day 0, every week, the integrity of the animals’ motor coordination was assessed using a Rota-rod 
apparatus measuring the number of falls from the rotating rod in a fixed time (600 s). Measurements were 
performed before and 24 h after FOLFOX administration (four administrations) during the first 4 weeks, 
and once a week, during treatments with dimiracetam, pregabalin and duloxetine. Each value represents the 
mean ± SEM of ten rats per group, performed in two different experimental sets
Day Treatments
Vehicle + vehicle FOLFOX + vehicle FOL-
FOX + dimiracetam
FOL-
FOX + prega-
balin
FOL-
FOX + dulox-
etine
0 4.0 ± 1.0 4.4 ± 0.4
1 1.3 ± 0.3 0.7 ± 0.2
7 1.0 ± 0.6 0.7 ± 0.2
8 0.0 ± 0.0 0.0 ± 0.0
14 2.0 ± 1.5 1.9 ± 0.5
15 0.0 ± 0.0 0.5 ± 0.3
21 2.0 ± 1.5 1.9 ± 0.6
22 1.2 ± 0.5 1.5 ± 0.5 1.2 ± 0.3 1.0 ± 0.9 1.5 ± 0.6
28 0.8 ± 0.3 1.0 ± 0.3 0.8 ± 0.5 1.0 ± 0.7 1.2 ± 0.8
35 1.0 ± 0.6 0.5 ± 0.3 1.4 ± 1.2 1.3 ± 0.4 1.4 ± 1.2
42 0.7 ± 0.7 0.8 ± 0.3 0.0 ± 0.0 0.5 ± 0.4 0.2 ± 0.2
49 0.0 ± 0.0 1.2 ± 1.3 0.6 ± 0.4 0.0 ± 0.0 0.0 ± 0.0
63 0.0 ± 0.0 0.3 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Table 5  HT-29 cell viability after 24 and 48 h incubation
HT-29 cells were treated with increasing concentrations of FOLFOX components in the presence or in the absence of 100 μM dimiracetam. 
Incubation was allowed for 24 h or 48 h. Cell viability was measured by MTT assay. Control condition was arbitrarily set as 100% and values are 
expressed as the mean ± SEM of three experiments
***P < 0.001 in comparison with control (FOLFOX 0 μM)
FOLFOX concentration (μM) Cell viability %
24 h incubation 48 h incubation
Control Dimiracetam (100 μM) Control Dimiracetam (100 μM)
Oxaliplatin 0 100 ± 3.95 100 ± 3.63 100 ± 3.95 100 ± 3.63
5-Fluorouracil 0
Leucovorin 0
Oxaliplatin 0.3 97.50 ± 3.80 105.33 ± 3.98 104.96 ± 4.74 96.32 ± 5.21
5-Fluorouracil 7.7
Leucovorin 3.5
Oxaliplatin 1 91.22 ± 2.46 106.20 ± 3.22 108.49 ± 3.54 95.83 ± 4.80
5-Fluorouracil 25.6
Leucovorin 11.6
Oxaliplatin 3 107.17 ± 4.45 100.13 ± 5.24 102.99 ± 6.36 92.40 ± 3.05
5-Fluorouracil 76.8
Leucovorin 35
Oxaliplatin 10 91.76 ± 2.89 63.27 ± 3.02*** 96.68 ± 4.20 61.55 ± 2.06***
5-Fluorouracil 256
Leucovorin leucovorin 136 µM 116
Oxaliplatin 30 66.52 ± 2.60*** 36.92 ± 1.54*** 72.90 ± 2.57*** 35.14 ± 0.41***
5-Fluorouracil 768
Leucovorin leucovorin 410 µM 348
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Noteworthy, current pharmacotherapy of FOLFOX-
dependent neuropathy was developed by modelling pain 
using oxaliplatin alone (in vitro or in vivo) without consid-
ering the complications introduced in humans by the pres-
ence of 5-FU and LV. In the present preclinical model of 
FOLFOX-induced neuropathy, duloxetine, and at a lesser 
extent morphine or pregabalin, was active after an acute 
administration. Duloxetine exerted the longest action in 
comparison with the other two compounds, while mor-
phine is the less effective, confirming the low effective-
ness of opioids in CINs [34]. Interestingly, in the pre-
sent experiments emerged that the effect of duloxetine is 
symptomatic only since a repeated twice daily treatment 
does not evoke a prolonged, all day long, pain relieving 
action. Pregabalin took a “preventive” effect (evaluated as 
a relief maintained over 24 h) after 14 days of treatment. 
Morphine was not repeatedly administered, since the well-
known development of tolerance to the anti-nociceptive 
effect [35, 36].
The racetam derivative dimiracetam was not effective 
after a single administration. On the contrary a repeated 
treatment fully reduced the FOLFOX-induced hypersen-
sitivity starting after 7 days of treatment. The effect was 
long lasting (at least 24 h) without the development of tol-
erance. Moreover, dimiracetam reduced the behavioural, 
neurological, and autonomic alterations evoked by the anti-
neoplastic agents. Racetam, even called nootropics, are a 
family of 2-pyrrolidinone derivatives designed in the sixties 
and profiled as cognition enhancers. Racetam compounds, 
such as nefiracetam and levetiracetam, have shown anti-
hyperalgesic effect in animal models of neuropathic pain 
[37, 38]. Dimiracetam itself has been already reported to be 
active against neuropathy induced by the chronic constric-
tion injury of the sciatic nerve and diabetic neuropathy [39]. 
Moreover, dimiracetam was effective in preclinical models 
of chemotherapy-induced neuropathic pain triggered by the 
anticancer compounds oxaliplatin or sorafenib or by antiret-
roviral drugs [14, 40]. To note, the racetam derivative as 
well as pregabalin act throughout the glutamatergic system, 
since pregabalin reduces the release of synaptic vesicles 
from glutamatergic neurons [41], and dimiracetam decreases 
the NMDA-induced release of glutamate in synaptosomal 
preparations from rat spinal cord [14]. Recently, we reported 
that the glutamate release was enhanced in cerebrocortical 
nerve terminals of oxaliplatin-treated rats [42]. Further-
more, astrocytes, major players in the oxaliplatin-induced 
chronic neuropathy, once activated, amplify glutamate sig-
nals acting on presynaptic AMPA receptors [43]. These evi-
dences suggest that the central nervous system is a primary 
target of the racetam compound. It is relevant to note the 
absence of interaction between dimiracetam and the lethal 
effect exerted by FOLFOX on the human colon cancer cells 
HT-29, suggesting a safety profile when used in combination 
with anticancer agents. Dimiracetam is currently in clinical 
development for treatment and/or prevention of CIN.
Conclusion
Our results describe for the first time a protocol of FOL-
FOX administration able to induce in the rat the onset of 
a chronic neuropathy characterized by hypersensitivity to 
mechanical and thermal (cold) stimuli as well as impair-
ment of behavioural, neurological, and autonomic param-
eters. Dimiracetam, repeatedly administered, completely 
counteracts FOLFOX-induced neuropathic alterations. The 
optimal safety profile of this compound suggests its possible 
use as treatment of the FOLFOX-induced neuropathy.
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